Ucb Biosciences, Inc.
Clinical trials sponsored by Ucb Biosciences, Inc., explained in plain language.
A subsidiary of UCB, a global biopharmaceutical company focused on neurology and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug cocktail shows promise for rare muscle disease
Disease control OngoingThis phase 2 study tests a combination of two nucleoside drugs, doxecitine and doxribtimine, in 47 people with thymidine kinase 2 (TK2) deficiency, a rare genetic disorder that weakens muscles. Participants already receiving nucleoside therapy continue treatment to see if the dru…
Phase: PHASE2 • Sponsor: UCB BIOSCIENCES, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for infants with severe epilepsy: fenfluramine trial launches
Disease control OngoingThis phase 3 trial is testing the safety and tolerability of fenfluramine (Fintepla) in 25 infants aged 1 to 2 years with Dravet syndrome, a severe form of epilepsy. The drug is given as an oral solution twice daily alongside other seizure medications. Researchers will monitor he…
Phase: PHASE3 • Sponsor: UCB BIOSCIENCES, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC